Verastem (VSTM) Change in Accured Expenses (2011 - 2026)
Verastem (VSTM) posted quarterly Change in Accured Expenses of -$3.1 million for Q1 2026, down 215.05% year-over-year from $2.7 million in Q1 2025, and down 133.34% quarter-over-quarter from $9.2 million in Q4 2025.
Analysis
Verastem (VSTM) Change in Accured Expenses (2011 - 2026) Analysis & Trends
Verastem's Change in Accured Expenses history runs 16 years deep, the most recent figure standing at -$3.1 million for Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 215.05% year-over-year to -$3.1 million; the TTM figure through Mar 2026 stood at $25.1 million (up 124.0% YoY), while the FY2025 annual figure was $30.8 million, up 285.46% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$3.1 million, down from $9.2 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $15.0 million in Q3 2025, with the low at -$3.1 million in Q1 2026.
- The 5-year median for Change in Accured Expenses is $1.6 million (2023), against an average of $2.2 million.
- The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses sank 292.62% in 2022, then soared 2285.16% in 2025.
- Verastem's Change in Accured Expenses stood at $195000.0 in 2022, then surged by 724.1% to $1.6 million in 2023, then jumped by 134.41% to $3.8 million in 2024, then surged by 144.01% to $9.2 million in 2025, then tumbled by 133.34% to -$3.1 million in 2026.
- Business Quant data shows VSTM's Change in Accured Expenses at -$3.1 million in Q1 2026, $9.2 million in Q4 2025, and $15.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Verastem | 814.94 Mn | 678.59 Mn | 36.32 Mn | 3.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.20 Mn |
| Mar 31, 2026 | -3.07 Mn |
| Dec 31, 2025 | 9.19 Mn |
| Sep 30, 2025 | 15.00 Mn |
| Jun 30, 2025 | 3.98 Mn |
| Mar 31, 2025 | 2.66 Mn |
| Dec 31, 2024 | 3.77 Mn |
| Sep 30, 2024 | 4.96 Mn |
| Jun 30, 2024 | -182,000.00 |
| Mar 31, 2024 | -544,000.00 |
| Dec 31, 2023 | 1.61 Mn |
| Sep 30, 2023 | 2.97 Mn |
| Jun 30, 2023 | -594,000.00 |
| Mar 31, 2023 | -1.05 Mn |
| Dec 31, 2022 | 195,000.00 |
| Sep 30, 2022 | -2.87 Mn |
| Jun 30, 2022 | 4.49 Mn |
| Mar 31, 2022 | -2.45 Mn |
| Dec 31, 2021 | 3.41 Mn |
| Sep 30, 2021 | 1.49 Mn |